8
Sep
2022

Amylyx’s ALS Surprise, Regeneron’s Eye Franchise Win & Roche Buys Good

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Merck Bets on the Eye, Merus Raises a Fortune, & Roche Leadership Change
Biogen Buys HI-Bio, Endeavor Reverses Lung Scarring, & Pfizer’s Latest Cuts